From: Proceedings of the 28th European Paediatric Rheumatology Congress (PReS 2022)
 | Pamidronate | Zoledronate | p-value |
---|---|---|---|
Clinical onset | |||
 Fever, n (%) | 2 (33,3%) | 0 | 0,051 |
 Pain, n (%) | 6 (100%) | 10 (100%) | - |
 Swelling, n (%) | 2 (33,3%) | 6 (60,0%) | 0,302 |
 Number of inflammatory foci, average±SD | 2,67±1,75 | 1,90±0,99 | 0,278 |
 Clinical evolution length, median (IQR) (months) | 3,00 (1,12-9,75) | 0,50 (0,29-7,00) | 0,280 |
Laboratory data | |||
 CRP, median (IQR) | 10,00 (7,20-24,55) | 5,40 (2,90-17,10) | 0,354 |
 ESR, average±SD | 36,20 ± 19,01 | 26,37 ± 21,06 | 0,415 |